Should I buy or sell Jounce Therapeutics stock right now?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 hold rating, 4...
What is Jounce Therapeutics' stock price forecast for 2022?
6 brokerages have issued 1 year target prices for Jounce Therapeutics' stock. Their forecasts range from $7.00 to $20.00. On average, they expect J...
How has Jounce Therapeutics' stock performed in 2022?
Jounce Therapeutics' stock was trading at $8.35 at the beginning of the year. Since then, JNCE shares have decreased by 59.8% and is now trading at...
When is Jounce Therapeutics' next earnings date?
Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were Jounce Therapeutics' earnings last quarter?
Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings data on Thursday, May, 5th. The company reported ($0.72) EPS for the quarter,...
Who are Jounce Therapeutics' key executives?
Jounce Therapeutics' management team includes the following people: Dr. Richard Murray Ph.D. , Pres, CEO & Director (Age 63, Pay $884.86k) Ms. K...
What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?
45 employees have rated Jounce Therapeutics CEO Richard Murray Ph.D on Glassdoor.com . Richard Murray Ph.D has an approval rating of 97% among Jou...
Who are some of Jounce Therapeutics' key competitors?
Some companies that are related to Jounce Therapeutics include NanoString Technologies (NSTG) , Osiris Therapeutics (OSIR) , iTeos Therapeutics...
What other stocks do shareholders of Jounce Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL)...
When is Jounce 2021?
What is Jounce Therapeutics?
(NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president will participate in a fireside chat at the Raymond James Human Health Innovation Conference, taking place virtually on Monday, June 21, 2021 at 12:40 p.m. ET. A webcast of the fireside chat will be a
About Jounce Therapeutics
(NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the U.S. Food and Drug Administration’s (FDA) clearance of its Investigational New Drug (IND) application for JTX-1811, an anti-CCR8 antibody, for which Gilead Sciences, Inc. (Nasdaq: GILD) has exclusive rights to develop and commercialize. The IND clearance trigge
Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which treats cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients.
What is Jounce Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Jounce Therapeutics stock. View analyst ratings for Jounce Therapeutics or view top-rated stocks.
Does market cap include convertible securities?
Jounce Therapeutics Inc is a clinical stage immunotherapy company. It is engaged in developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. The company primarily operates only in the United States. The company have developed a suite of integrated technologies that comprise Translational Science Platform, enabling it to comprehensively interrogate the cellular and molecular composition of tumors.
